Abstract
Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.
| Original language | English |
|---|---|
| Pages (from-to) | 1489-1493 |
| Number of pages | 5 |
| Journal | Anticancer Research |
| Volume | 37 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2017 |
Fingerprint
Keywords
- Bevacizumab
- Childhood
- Hepatocellular carcinoma
- Liver transplantation
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma : A single-center experience. / De Pasquale, Maria Debora; De Goyet, Jean De Ville; Monti, Lidia; Grimaldi, Chiara; Crocoli, Alessandro; Castellano, Aurora.
In: Anticancer Research, Vol. 37, No. 3, 01.03.2017, p. 1489-1493.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma
T2 - A single-center experience
AU - De Pasquale, Maria Debora
AU - De Goyet, Jean De Ville
AU - Monti, Lidia
AU - Grimaldi, Chiara
AU - Crocoli, Alessandro
AU - Castellano, Aurora
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.
AB - Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.
KW - Bevacizumab
KW - Childhood
KW - Hepatocellular carcinoma
KW - Liver transplantation
UR - http://www.scopus.com/inward/record.url?scp=85015863734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015863734&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11475
DO - 10.21873/anticanres.11475
M3 - Article
C2 - 28314323
AN - SCOPUS:85015863734
VL - 37
SP - 1489
EP - 1493
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 3
ER -